IJTLD Open (ISSN: 3005-7590) is open access and fully compliant with Plan S.
IJTLD Open includes a broader range of article types than the traditional IJTLD, including: Editorials, Meeting reports, Original Articles (including methodology papers, qualitative research and operational research), State of the Art Reviews, Guidelines/Consensus documents, Systematic Reviews and Meta-Analysis, Perspectives, Minireviews, Letters, Case reports, Case series and Correspondence.
We publish high impact research for the continuing education of academics, clinicians and all other health personnel working on respiratory diseases and lung health, with the aim of improving policy and practise.
IJTLD OPEN is open access and free to read. Also, authors retain copyright and can freely distribute the PDF or upload it to any website. As a consequence, open access articles are highly downloaded and more highly cited.
Click the links below to read our content on PubMed Central, Ingenta.com or via links from the Directory of Open Access Journals (DOAJ), or PubMed. .
While preparing their article, authors should refer to the Instructions for Authors to check that they have complied with our requirements – see links below.
Once complete, authors should submit their manuscripts at http://mc.manuscriptcentral.com/ijtld
We invite authors with OA funding to submit their papers (including Editorials, Original Articles, Letters and Case Series) to IJTLD OPEN.
We welcome submissions on the development of vaccines, diagnostics and medicines for the prevention, management and control of TB and all other respiratory diseases.
This includes basic, translational, clinical, epidemiological and programmatic research relevant to the Union’s mission to find health solutions for these conditions.
For all queries please e-mail the Editorial Office
Sponsorship
Supplements and article series are a highly-effective way of highlighting a specific topic to researchers, clinicians and decision makers in respiratory health.
Being an Open Access journal, IJTLD OPEN has no barriers to access and can reach readers in health centres, medical, university and pharmaceutical institutes, along with civil society, patients and carers.
All content will be freely available on Ingenta.com and we will have regular mailings to highlight the latest sponsored content.
Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD, IJTLD OPEN and PHA and publishing them in full on our website, prior to their publication in the Journals. Read fast-track articles:
Responding to COVID-19: adjusting TB services in a low-burden setting
A letter to the editors in which the Victorian Tuberculosis Program describes how the social and programmatic changes to TB services brought on by COVID-19 have been experienced in practice.
COVID-19 in Africa: community and digital technologies for tuberculosis management
This letter explores the concerns about the negative impact that COVID-19 will have on the fight against tuberculosis in Africa
A decrease in tuberculosis evaluations and diagnoses during the COVID-19 pandemic
This letter looks at the implications and potential consequences of delayed or missed diagnoses for TB, which may increase TB-related hospitalisations and death.
COVID-19 and tuberculosis—threats and opportunities
In an editorial to the IJTLD, the authors state how we must overcome the challenges that COVID-19 presents and use the opportunities it affords us to achieve a paradigm shift in TB treatment and care
Common concerns in managing bronchial asthma during the COVID-19 pandemic
A letter to the editors of the IJTLD addresses the major concern of use of corticosteroids and nebulised bronchodilators in bronchial asthma during the COVID-19 pandemic
Severe COVID-19 cases with a history of active or latent tuberculosis
In a letter to the editors, authors report on symptom development, disease progression and treatment for three cases, each representing a different TB scenario.